adb-logo
FDA Advisory Committee Panel Meetings: What to Expect

What to Expect in FDA Advisory Committee Panel Meetings

High-risk or novel devices may require FDA Advisory Committee review. Learn the process, timeline, and preparation strategies—from briefing books to public hearings—to navigate panels confidently and maximize the chance of a smooth regulatory outcome.

Frame-5

← Back to FDA Meeting Prep & Representation

For high-risk or novel medical devices, the FDA may convene an Advisory Committee panel meeting as part of the premarket review. These meetings can be pivotal – they are public, often high-stakes hearings where a panel of external experts evaluates the safety and effectiveness of a device and provides a recommendation to the FDA. If your device is headed to an advisory panel, it’s critical to understand the format, timeline, and expectations of these meetings. This section demystifies the advisory committee process for medical devices and offers guidance on how to navigate it successfully.

What is an FDA Advisory Committee Panel?

The FDA’s Medical Devices Advisory Committee is an assembly of independent experts (such as physicians, scientists, biostatisticians, and patient representatives) that the FDA consults for advice on complex device approvals. When a device is first-of-a-kind or presents difficult benefit-risk questions, FDA often seeks the panel’s recommendation before making a decision. In fact, FDA policy is that “all PMAs for a first-of-a-kind device are taken before the appropriate advisory panel for review and recommendation.” The panel’s role is advisory – they vote on specific questions (for example, whether a device’s benefits outweigh its risks for the intended use). While the FDA is not bound by the panel’s vote, the Agency generally takes the advice very seriously as part of its decision-making.

advisory-commite

Key Stages of the Advisory Committee Process

Panel Meeting Scheduling If FDA decides a panel is needed, you will be notified, and a meeting date is set (often several months out). The FDA publishes a Federal Register notice announcing the panel meeting, including the questions to be addressed. Sponsors typically have ~8+ weeks from notification to the meeting date.
Briefing Book Preparation As the sponsor, you must prepare a briefing document (often 100+ pages) that is provided to panel members and made public. According to FDA guidance, sponsors should “develop, organize, and submit advisory committee briefing materials” well in advance for FDA review. This document contains an executive summary, detailed device description, summary of preclinical and clinical data, proposed indications, and discussion of any issues. FDA will also prepare its own briefing memo. Both documents are released publicly (usually 2 weeks before the meeting) so that panel members and the public can review the information. Expect that everything in your briefing book will be scrutinized, so it must be accurate and clear.
Pre-Panel Preparations In the weeks leading up, you will likely engage in dry runs or mock panels. Many companies conduct practice sessions with internal staff or consultants playing the role of panel members, asking tough questions. This preparation is invaluable. You may also meet with FDA (informally) to confirm meeting logistics or clarify the panel questions. FDA staff might give you preliminary feedback on your presentation slides to ensure accuracy.
Day of the Meeting – Format Advisory committee meetings are public and follow a set agenda. Typically, the FDA will give an opening presentation summarizing the device and the review issues. Then the sponsor (your team) gives a formal presentation, often 30-60 minutes, making the case for your device’s approval (covering unmet medical need, key study results, risk/benefit argument, etc.). There is usually an Open Public Hearing portion where clinicians, patients, or other stakeholders can offer comments (these could be supportive or raise concerns). Then, the panel Q&A and discussion begins – panel members can ask questions to both FDA and the sponsor. This is often the most intensive part, as experts probe the data deeply. Finally, the panel will be asked to vote on one or more questions. Commonly, they vote on whether they believe the device should be approved, approved with conditions, or not approved, based on safety and effectiveness data. Each panel member may also explain the rationale for their vote.

What to Expect as a Sponsor?

  • Intense Scrutiny:
    Panel members will have read both your briefing book and FDA’s analysis. Expect detailed questions on any weaknesses in your data. For example, if your clinical trial had missing data or subgroup issues, be prepared to explain. Panelists may also ask about device specifics, bench testing, post-market plans, and compare your product to current standards of care. It can feel like a thesis defense – remain calm and address questions truthfully and directly. If you don’t know an answer, it’s better to say you will follow up or acknowledge the limitation rather than evade.
  • FDA’s Stance:
    Pay attention to FDA’s presentation and comments. Often, FDA staff will outline concerns they have (perhaps regarding a safety signal or whether efficacy data meets the bar). These are hints to what the Agency sees as the crux of the decision. You should address these concerns head-on in your presentation and responses.
  • Panel Dynamics:
    The panel will have diverse perspectives – some members may be more risk-averse, others more enthusiastic about innovation. The panel chair runs the meeting to ensure everyone’s questions are heard. As the sponsor, you should address the entire panel when answering (not just the person who asked), since all will vote. Also, be aware that there is often an FDA “designated federal officer” and other FDA staff facilitating; they ensure procedural fairness and that the meeting follows regulations (for instance, avoiding discussion of trade secrets in public).
  • Time Management:
    Your presentation time is strictly limited. Rehearse to make sure you convey key points within the allotted slot. In the Q&A, be concise – lengthy, rambling answers can consume time and frustrate panelists. A clear, 1-2 minute focused answer works best, with an offer to clarify further if needed.
sponsor

Tips for a Successful Panel Meeting

Start Preparations Early Once you know a panel is likely, begin assembling your core team (regulatory, clinical, statistical, etc.) to craft the strategy. Timeline: FDA’s guidance suggests timelines for submitting briefing materials; typically, you must get the final briefing book to FDA at least several weeks before the meeting for public posting. Work backwards from the meeting date to set internal deadlines.
Craft a Clear Narrative The panel briefing book and presentation should tell a coherent story. Emphasize the device’s clinical benefit and how the data support it. Acknowledge known risks or limitations, but contextualize them (e.g. compare to standard of care outcomes). Panel experts appreciate when a sponsor is forthcoming about weaknesses and provides a rationale or mitigation plan.
Anticipate Panel Questions As part of preparation, list every tough question you can imagine (scientific, regulatory, even business-related if relevant). Develop well-thought-out answers for each. For instance, “What happens if the device fails during use – is there a backup?” or “Why did 10% of patients in your trial withdraw – could that bias results?” Having a prepared answer (and slide, if appropriate) ensures you won’t be caught off guard.
Use Visuals Wisely In your oral presentation, use slides to illustrate key data – but don’t overcrowd them. Panel members will have the detailed data in the briefing book; slides should highlight the take-home points (e.g., a chart of primary endpoint results vs. the performance goal). Ensure figures are clear and easy to read. The goal is to make it as easy as possible for panelists to see evidence of safety and effectiveness.
Plan the Roles Decide who will present each part and who will answer questions on various topics. Typically, the sponsor’s team might include a senior executive for introduction, a clinical expert (often the trial principal investigator) to present study results, a statistician for data analysis questions, an R&D engineer for technical questions, and a regulatory lead to handle process/regulation questions. Also consider including a key opinion leader (KOL) physician to speak on the device’s importance for patients – their external voice can carry weight.
Public Comment Strategy During the Open Public Hearing, supporters or detractors can speak. Sponsors often coordinate supportive voices (like a patient who benefitted from the device or a respected clinician) to call in or attend. While you cannot overly stage-manage this (FDA requires speakers to disclose affiliations), making sure the panel hears a patient perspective can be powerful.
Stay Professional and Responsive Panel meetings can become emotional or tense. Always remain professional, even if some comments are critical. Thank the panel for their insights. If a panelist misunderstands something about your device, calmly clarify with factual information. The FDA and panel will appreciate a sponsor who is transparent, scientifically grounded, and open to feedback. As FDA’s committee guidance states, these meetings are about exchange of information among FDA, industry, and the public, so be an active, respectful participant in that exchange.

After the Panel – What Then?

When the panel votes are in, the meeting adjourns. Typically, the panel’s recommendation (for or against approval) will be noted. The FDA will then deliberate internally, taking into account the panel’s views, and later issue a final decision on your application (approval, approvable with conditions, or not approval for PMAs; for De Novo or 510(k) with panel input, a clearance or denial decision). Do not be discouraged by a split or even negative vote – FDA has leeway. However, a strong positive vote is obviously a great sign. 

It’s important to note any conditions or concerns panelists raised. FDA may require you to address these (for example, through post-market studies or specific labeling changes) as a condition of approval. Also, thank your panel participants informally through FDA – they’ve spent significant time on your application. 

after-panel

The transcript of the meeting will become public within a few weeks. Review it to glean any nuances from the discussion. These insights can help in future interactions or submissions. 

Conclusion

FDA advisory committee meetings are often the most publicly visible step in a device’s approval journey. By knowing what to expect and preparing meticulously, sponsors can greatly influence the outcome. Many a device has won over a skeptical panel through solid data presentation and effective engagement with panelists’ questions. Treat the panel as a group of knowledgeable colleagues whose goal is the same as yours – to ensure safe and effective devices for patients. With that mindset, you can approach the meeting with confidence. Our team has supported clients through numerous advisory panels, from planning briefing materials to conducting realistic mock panels. With expert guidance, you can turn a nerve-wracking panel appearance into a well-managed opportunity to showcase your product’s value, moving you one step closer to FDA approval.

Contact Us to Navigate FDA Advisory Committee Panel Expectations

Contact Now
0 +

Customer Served

0 +

Product Launched

0 +

Regulatory Submissions